Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nestle and Phospha-E

This article was originally published in The Tan Sheet

Executive Summary

Nestle has exercised its option to finalize a commercial agreement to use Phosphagenics' Phospha-E as an ingredient in medical foods for treatment and prevention of metabolic syndrome, Phosphagenics announces Jan. 18. Nestle will pay the firm an option fee and both firms will begin human trials to "provide science-based evidence" for the ingredient, according to the terms of the agreement. The agreement also requires Nestle to launch a product containing Phospha-E within 12 months of regulatory approval. Phosphagenics will be responsible for manufacture and sales of the ingredient to Nestle. Nestle recently announced plans to expand its Nutritional division with the $2.5 bil. acquisition of Novartis' Medical Nutrition unit (1"The Tan Sheet" Dec. 18, 2006, p. 8)...
Advertisement

Related Content

Nestle Looks To Cook Up Nutrition Product Sales With Novartis MN Acquisition
Nestle Looks To Cook Up Nutrition Product Sales With Novartis MN Acquisition

Topics

Advertisement
UsernamePublicRestriction

Register

PS100141

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel